Stryker (NYSE:SYK) Given New $454.00 Price Target at Needham & Company LLC

Stryker (NYSE:SYK) had its price target lifted by stock analysts at Needham & Company LLC from $448.00 to $454.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 28.11% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research note on Friday, November 14th. TD Cowen cut Stryker from a “buy” rating to a “hold” rating and set a $387.00 price target for the company. in a report on Monday. Wells Fargo & Company lifted their price objective on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a research report on Friday, December 19th. Finally, Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price for the company in a research note on Tuesday, January 6th. Twelve research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $426.39.

Stryker Price Performance

SYK opened at $354.39 on Friday. Stryker has a 52-week low of $329.16 and a 52-week high of $404.87. The company has a 50 day moving average of $359.38 and a two-hundred day moving average of $371.95. The company has a market cap of $135.53 billion, a P/E ratio of 46.57, a P/E/G ratio of 2.29 and a beta of 0.89. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the prior year, the company earned $4.01 EPS. The firm’s revenue was up 11.4% on a year-over-year basis. On average, analysts expect that Stryker will post 13.47 earnings per share for the current year.

Insider Activity at Stryker

In other news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 522,118 shares of company stock valued at $185,381,932 over the last three months. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SYK. Mid American Wealth Advisory Group Inc. bought a new position in Stryker in the second quarter worth about $26,000. Clayton Financial Group LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker in the 3rd quarter worth approximately $27,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker during the 2nd quarter valued at approximately $28,000. Finally, Sachetta LLC boosted its position in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat — Stryker posted Q4 adjusted EPS $4.47 (vs. $4.40 consensus) and revenue $7.17B, with organic sales up ~11% and adjusted operating margin expanding 100 bps, signaling continued top?line momentum and operating leverage. Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Raised outlook/supportive commentary — Management now guides 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10 and indicated modestly favorable pricing and FX, prompting firms to keep/confirm Buy ratings. Reuters notes management raised its profit forecast tied to strong capital and implant demand. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analyst support — Multiple shops (Needham, Piper Sandler and others) reiterated Buy/Overweight ratings after the results, citing sustained double?digit growth in key MedSurg/Neuro businesses and improved margins. Stryker: Sustained Double-Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: FY26 EPS range roughly in line with consensus — the $14.90–$15.10 range centers near Street estimates (consensus ~14.96). That calmingly conservative guidance reduces upside surprise potential and helps explain muted share reaction despite the beat.
• Neutral Sentiment: Earnings call / details available — full Q4 earnings call transcript and company presentation provide more color on product momentum, capital demand and margin drivers for investors reviewing catalysts. Stryker Q4 2025 Earnings Call Transcript
• Negative Sentiment: Tariff/regulatory risks flagged — some analysts and the company note potential 2026 tariff headwinds and geopolitical/regulatory risks that could pressure margins or growth in certain markets if they materialize.
• Negative Sentiment: Large insider selling noted by data providers — recent public filings and data aggregators show substantial insider share sales over the past 6 months, which can amplify sell?side pressure or signal near?term positioning changes. QuiverQuant summary & insider activity
• Negative Sentiment: Product/segment items — notable declines or one?time items (e.g., a material drop in spinal implants year/quarter comparisons and earlier goodwill/impairment charges) remain on the P&L and are potential longer?term headwinds for parts of Orthopaedics. Stryker reports 2025 operating results and 2026 outlook

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.